



ISMAIL
INDUSTRIES
LIMITED

GROWING

INTO NEW
HORIZONS

QUARTERLY REPORT
MARCH 31, 2022

TABLE OF CONTENTS

Company Profile	02
-----------------------	----

Director's Review Report (Eng & Urdu)	03-04
---------------------------------------------	-------

Unconsolidated Condensed Interim Statement of Financial Position	06
------------------------------------------------------------------------	----

Unconsolidated Condensed Interim Statement of Profit or Loss &	
----------------------------------------------------------------	--

Other Comprehensive Income	07
----------------------------------	----

Unconsolidated Condensed Interim Statement of Changes in Equity	08
-----------------------------------------------------------------------	----

Unconsolidated Condensed Interim Statement of Cash Flows	09
----------------------------------------------------------------	----

Notes to The Unconsolidated Condensed Interim Financial Statements	10-19
--------------------------------------------------------------------------	-------

Consolidated Condensed Interim Statement of Financial Position	22
----------------------------------------------------------------------	----

Consolidated Condensed Interim Statement of Profit or Loss &	
--------------------------------------------------------------	--

Other Comprehensive Income	23
----------------------------------	----

Consolidated Condensed Interim Statement of Changes in Equity	24
---------------------------------------------------------------------	----

Consolidated Condensed Interim Statement of Cash Flows	25
--------------------------------------------------------------	----

Notes to The Consolidated Condensed Interim Financial Statements	26-34
------------------------------------------------------------------------	-------



COMPANY PROFILE

Board of Directors

Mr. Muhammad M. Ismail	Chairman
Mr. Munсарim Saifullah	Chief Executive Officer
Mr. Ahmed Muhammad	Executive Director
Mr. Maqsood Ismail	Non-Executive Director
Mr. M. Zubair Motiwala	Independent Director
Ms. Tasneem Yusuf	Independent Director

Audit Committee Members

Ms. Tasneem Yusuf	Chairperson
Mr. Muhammad M. Ismail	Member
Mr. Maqsood Ismail	Member

Registered Office

17, Bangalore Town,
Main Shahrah-e-Faisal, Karachi

Factories

Unit-1: C-230, Hub H.I.T.E.,
Balochistan, Pakistan.

Unit -2: B-140, Hub H.I.T.E.,
Balochistan, Pakistan.

Unit-3: G-1, Hub H.I.T.E.,
Balochistan, Pakistan.

Unit-4: G-22, Hub H.I.T.E.,
Balochistan, Pakistan.

Unit-5: 38-C, Sundar Industrial Estate
Raiwind Road, Lahore, Pakistan.

Unit-6: D-91,D-92 & D-94 North Western Zone,
Port Qasim, Karachi, Sindh, Pakistan.

Unit-7: E164-168, North Western Zone,
Port Qasim, Karachi, Sindh, Pakistan.

Unit-8: E154-157, North Western Zone,
Port Qasim, Karachi, Sindh, Pakistan.

Unit-9: G-1, Hub H.I.T.E.,
Balochistan, Pakistan.

Human Resource & Remuneration Committee

Mr. M. Zubair Motiwala	Chairman
Mr. Maqsood Ismail	Member

Company Secretary

Mr. Ghulam Farooq

Chief Financial Officer

Mr. Abdul Qadir

Auditor

Grant Thornton Anjum Rahman
Chartered Accountants

Legal Advisor

Mohsin Tayebaly& Co.

Share Registrar

THK Associates (Pvt.) Limited

Bankers / Institutions

Allied Bank Limited
Askari Bank Limited
Bank Alfalah Limited
Bank Al-Habib Limited
Bank Islami Pakistan Limited
Dubai Islamic Bank (Pakistan) Limited
Faysal Bank Limited
Habib Bank Limited
Habib Metropolitan Bank Limited
Industrial & Commercial Bank of China Limited
JS Bank Limited
MCB Bank Limited
MCB Islamic Bank Limited
Meezan Bank Limited
National Bank of Pakistan
PAIR Investment Company Limited
Pak Brunei Investment Co Ltd
Pak Oman Investment Co. Ltd
Soneri Bank Limited
Standard Chartered Bank (Pakistan) Limited
The Bank of Punjab

DIRECTOR'S REVIEW REPORT

The Board of Directors of the Company are pleased to present the standalone and consolidated un-audited condensed interim financial statements of the Company for the quarter and nine months period ended March 31, 2022. The overview on Company's performance during the period under review is here under:

Description	31-Mar-2022	31-Mar-2021	Change in %
	PKR in Million		
Gross Sale	49,280	35,276	40%
Gross Profit	7,478	5,920	26%
Operating Profit	3,089	1,933	60%
Profit after tax	1,898	1,501	26%
EPS in Rs.	28.60	22.62	26%

The Pakistan's economy is still on the path of its struggling to the recovery despite the current account deficits, depreciating currency, reduction in foreign exchange reserves and rising inflation. However, inflationary trends on the back of increasing international commodity prices along with the upward trend of interest rates does pose certain uncertainties which may impact the consumer spending. However, the Company has successfully ended its nine months period with encouraging financial performance based on strong growth in sales and earnings.

The growth momentum continued as the Company reported 40% increase in gross sale and 26% in profit after tax for the period under review versus same period of last year. This has been achieved through volumetric growth from its existing customers and further exploring local and international markets. We are very much optimistic about substantial growth in capitalizing our strong brand equity and a highly committed workforce along with focus on R&D, product management and continuous initiatives for operational excellence.

The Company will keep its focus on diversification, vertical and horizontal integration, technological advancement and transformation and informed portfolio investment and this will lead for the strategic decision making of the Board of Directors. Equity investment in Subsidiary Company, M/s. Ismail Resin (Private) Limited and capital investment for flour mill will hedge the Company from future supply chain shocks and upside risk of inflation.

FUTURE OUTLOOK

Improvements in business environment will largely depends on the economic policies of the government and the implementation of key reforms. We foresee that the current recorded high commodity prices, increasing interest rate, and global supply chain disruptions will continue in upcoming periods, and likely to keep the inflation trend at an elevated level. The management is closely monitoring the evolving economic situation and analyzing its impact over Company's performance, while concentrating on consistency and sustainability in business operations and preserving the value of stakeholders through capitalizing its rich experience and business understanding.

ACKNOWLEDGEMENT

The Board of Directors expresses their gratitude and heartfelt appreciation to all stakeholders for confidence, continued support and encouragement.

On behalf of the Board of Directors

Munsarim Saifullah

Chief Executive Officer

Karachi: April 22, 2022

Maqsood Ismail

Director

ڈائریکٹران کی جائزہ رپورٹ

کمپنی اپنی توجہ تنوع، عمودی اور افقی انضمام، تکنیکی ترقی اور تبدیلی اور باخبر پورٹ فولیو سرمایہ کاری پر مرکوز رکھے گی اور یہ بورڈ آف ڈائریکٹرز کے حکمت عملی کے تحت فیصلہ سازی کا باعث بنے گی۔ ڈیلی کمپنی میں ایکویٹی سرمایہ کاری، اسماعیل ریزین (پرائیویٹ) لمیٹڈ اور فلوویل کے لیے سرمایہ کاری، کمپنی کو مستقبل میں اشیاء کی فراہمی کے تسلسل کو متاثر کرنے اور افراط زر کے نقصان سے محفوظ رکھے گی۔

کمپنی کے ڈائریکٹرز انتہائی مسرت کے ساتھ 31 مارچ 2022 تک کے سرمایہ اور نو ماہ کی مدت کے لیے کمپنی کے انفرادی و مشترکہ غیر آڈٹ شدہ نتائج پیش کر رہے ہیں۔ زیر جائزہ مدت کے دوران کمپنی کی کارکردگی کا جائزہ درج ذیل ہے۔

تفصیل	مارچ 2022	مارچ 2021	تبدیلی %
	پاکستانی روپے ملین میں		
کھوپری فروخت	49,280	35,276	40%
نفاذ نتائج	7,478	5,920	26%
کھوپری نتائج	3,089	1,933	60%
نتائج بعد از حصول	1,898	1,501	26%
فی شخص آمدن	28.60	22.62	26%

مستقبل کی پیش بینی

کاروباری ماحول میں بہتری کا زیادہ تر انحصار حکومت کی معاشی پالیسیوں اور کلیدی اصلاحات کے نفاذ پر ہوگا۔ ہم پیش گوئی کرتے ہیں کہ اجناس کی موجودہ ریکارڈ شدہ بلند قیمتیں، بہتر ہوئی شرح سود اور عالمی سطح پر اشیاء کی فراہمی میں رکاوٹیں آنے والے ادوار میں بھی جاری رہیں گی اور افراط زر کے رجحان کو بلند سطح پر رکھنے کا امکان ہے۔ انتظامیہ ابھرتی ہوئی اقتصادی صورت حال پر گہری نظر رکھے ہوئے ہے اور کمپنی کی کارکردگی پر اس کے اثرات کا تجزیہ کر رہی ہے، جبکہ کاروباری کارروائیوں میں مستقل مزاجی اور اپنا انداز پر توجہ مرکوز رکھے ہوئے ہے اور اس بھرپور تجربے اور کاروباری کچھ بوجھ سے فائدہ اٹھا کر متعلقین کی قدر کو محفوظ کر رہی ہے۔

اعتراف

بورڈ آف ڈائریکٹرز اعتماد، مسلسل تعاون اور حوصلہ افزائی کے لیے تمام متعلقین کا قلب کی گہرائیوں سے تحریف کرتے ہیں اور مشکور ہیں۔

من جانب بورڈ آف ڈائریکٹرز

مقصود اسماعیل
ڈائریکٹر

منصر سیف اللہ
چیف ایگزیکٹو آفیسر

کمپنی کی ترقی کی رفتار جاری ہے کیونکہ کمپنی نے گزشتہ سال کی اسی مدت کے مقابلے میں زیر جائزہ مدت کے لیے مجموعی فروخت میں 40% اور منافع بعد از حصول میں 26% اضافہ ظاہر کیا۔ یہ اپنے موجودہ صارفین کی جانب سے توجہ منواری اور بین الاقوامی منڈیوں کی مزید تلاش کے ذریعے حاصل کیا گیا ہے۔ ہم اپنی مضبوط برانڈ ایکویٹی اور انتہائی پر عزم انفرادی قوت کے ساتھ تحقیق و ترقی اور مصنوعات کی انتظام کاری پر توجہ مرکوز کرنے اور اعلیٰ مہارت کے لیے مسلسل اقدامات کی خاطر خواہ ترقی کے لئے بہت پر امید ہیں۔

کراچی: ۱۲ اپریل ۲۰۲۲

**UNCONSOLIDATED CONDENSED INTERIM
FINANCIAL INFORMATION (UN-AUDITED)
FOR THE NINE MONTHS PERIOD
ENDED MARCH 31, 2022**



UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION AS AT MARCH 31, 2022

	Note	(Un-audited) March 31, 2022	(Audited) June 30, 2021
		-----Rupees-----	
ASSETS			
Non-current assets			
Property, plant and equipment	7	23,940,670,867	20,797,301,134
Right-of-use assets	7.1	40,959,881	82,762,838
Intangible assets		9,450,950	33,730,783
Long term investments	8	5,880,123,553	5,277,725,078
Long term deposits		19,306,441	26,838,890
Total non-current assets		29,890,511,692	26,218,358,723
Current assets			
Stores and spares	9	483,185,901	459,511,285
Stock-in-trade	10	7,951,612,232	7,570,435,262
Trade debts	11	7,631,119,159	3,345,669,807
Loans and advances		2,071,260,187	1,529,096,136
Trade deposits and short-term prepayments		55,660,790	30,581,266
Short term investment		961,476,038	318,381,590
Other receivables		116,446,732	117,644,543
Taxation - net		1,291,784,042	1,256,736,585
Cash and bank balances	12	476,777,244	143,565,665
Total current assets		21,039,322,325	14,771,622,139
Total assets		50,929,834,017	40,989,980,862
EQUITY AND LIABILITIES			
Share capital and reserves			
Authorized share capital			
250,000,000 (June 30, 2021: 250,000,000) ordinary shares of Rs. 10 each		2,500,000,000	2,500,000,000
Issued, subscribed and paid-up share capital		663,569,400	663,569,400
Reserves		11,384,477,100	10,611,167,244
Total shareholders' equity		12,048,046,500	11,274,736,644
Non-current liabilities			
Long term finances - secured	13	15,542,746,364	12,890,753,566
Lease liabilities		-	19,401,180
Deferred liabilities		2,338,846,774	2,291,284,075
Total non-current liabilities		17,881,593,138	15,201,438,821
Current liabilities			
Trade and other payables	14	7,461,046,197	3,993,579,951
Accrued mark-up		276,116,928	162,665,518
Short term finances - secured	15	9,484,305,411	6,063,068,547
Current portion of:			
- long term finances - secured	13	3,397,432,002	3,672,098,318
- Lease liabilities		13,116,605	42,765,702
Unclaimed dividend		4,147,708	2,902,597
Advances from customers - unsecured		364,029,528	576,724,764
Total current liabilities		21,000,194,379	14,513,805,397
Total liabilities		38,881,787,517	29,715,244,218
Total equity and liabilities		50,929,834,017	40,989,980,862
Contingencies and commitments	16		

The annexed selected notes from 1 to 24 form an integral part of these unconsolidated condensed interim financial statements.

**UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022**

	Note	Nine-months Period Ended		Three-months Period Ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
		-----Rupees-----		-----Rupees-----	
Sales - gross	19.1	49,279,638,401	35,276,338,183	17,833,595,383	12,001,029,935
Sales returns and discounts		(1,904,847,178)	(1,504,439,193)	(765,477,555)	(519,599,347)
Export Rebate		22,879,618	13,691,682	1,903,288	2,895,813
		(1,881,967,560)	(1,490,747,511)	(763,574,267)	(516,703,534)
		47,397,670,841	33,785,590,672	17,070,021,116	11,484,326,401
Sales tax		(5,770,709,067)	(4,475,120,186)	(1,946,120,682)	(1,493,034,099)
Sales - net		41,626,961,774	29,310,470,486	15,123,900,434	9,991,292,302
Cost of sales	19.1	(34,149,202,410)	(23,390,919,540)	(12,464,102,106)	(7,816,552,192)
Gross profit		7,477,759,364	5,919,550,946	2,659,798,328	2,174,740,110
Selling and distribution expenses		(3,814,329,138)	(3,466,554,502)	(1,199,319,894)	(1,328,565,301)
Administrative expenses		(574,389,775)	(520,489,714)	(171,722,029)	(228,599,169)
Operating profit		3,089,040,451	1,932,506,730	1,288,756,405	617,575,640
Other operating expenses		(384,212,532)	(233,890,384)	(136,927,119)	(72,883,569)
		2,704,827,919	1,698,616,346	1,151,829,286	544,692,071
Other income		531,065,588	331,733,746	42,927,676	23,262,636
		3,235,893,507	2,030,350,092	1,194,756,962	567,954,707
Finance cost		(962,865,323)	(561,075,182)	(378,301,275)	(160,425,441)
		2,273,028,184	1,469,274,910	816,455,687	407,529,266
Share of profit from associated company - net		121,026,531	230,991,373	79,370,638	122,012,640
Profit before taxation		2,394,054,715	1,700,266,283	895,826,325	529,541,906
Taxation		(496,283,787)	(198,996,935)	(204,976,616)	65,434,303
Profit after taxation		1,897,770,928	1,501,269,348	690,849,709	594,976,209
Other Comprehensive Income / (loss)					
<i>Item that will not be reclassified to unconsolidated statement of profit or loss in subsequent periods</i>					
Unrealized loss on remeasurement of investment classified as fair value through OCI - net of tax		-	(3,663,600)	-	-
Share of other comprehensive (loss) from associated company - net of tax		(129,106,973)	(193,668,319)	(83,300,708)	(20,472,472)
Other comprehensive (loss) for the period - net of tax		(129,106,973)	(197,331,919)	(83,300,708)	(20,472,472)
Total comprehensive income for the period		1,768,663,955	1,303,937,429	607,549,001	574,503,737
Earnings per share - basic & diluted	20	28.60	22.62	10.41	8.97

The annexed selected notes from 1 to 24 form an integral part of these unconsolidated condensed interim financial statements.

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022

Issued, subscribed and paid-up share capital	Capital reserve		Total reserves			Total shareholders' equity	
	Share premium	Amalgamation reserves	Revenue reserves		Total reserves		
			Re-measurement of investment in associated company	Re-measurement of investments at fair value through OCI			
663,569,400	1,472,531,500	916,862,067	41,535,172	-	6,805,286,458	9,234,215,197	9,899,784,597
-	-	-	-	-	1,501,269,348	1,501,269,348	1,501,269,348
-	-	-	-	(3,663,600)	-	(3,663,600)	(3,663,600)
-	-	-	(193,668,319)	-	-	(193,668,319)	(193,668,319)
-	-	-	(193,668,319)	(3,663,600)	1,301,269,348	1,303,937,429	1,303,937,429
663,569,400	1,472,531,500	916,862,067	(152,133,147)	-	(199,070,820)	(199,070,820)	(199,070,820)
663,569,400	1,472,531,500	916,862,067	(152,133,147)	(3,663,600)	8,107,484,936	10,341,081,806	11,004,151,206
663,569,400	1,472,531,500	916,862,067	(191,924,445)	(3,857,616)	8,417,555,738	10,611,167,244	11,274,736,644
-	-	-	-	-	1,897,770,928	1,897,770,928	1,897,770,928
-	-	-	(129,106,973)	-	-	(129,106,973)	(129,106,973)
-	-	-	(129,106,973)	-	1,897,770,928	1,768,663,955	1,768,663,955
-	-	-	-	-	(995,354,099)	(995,354,099)	(995,354,099)
663,569,400	1,472,531,500	916,862,067	(321,031,418)	(3,857,616)	9,319,972,556	11,384,477,100	12,048,046,500

Balance as at July 01, 2020 - audited

Total comprehensive income/ (loss) for the period

Profit for the nine months period ended March 31, 2021

Unrealized loss on re-measurement of investment classified as fair value through OCI - net of tax

Share of other comprehensive loss from associated company - net of tax

Total comprehensive (loss) / income for the period

Transaction with owners, recognised directly in equity

Final cash dividend for the year ended June 30, 2020 @ Rs. 3 per share

Balance as at March 31, 2021

Balance as at July 01, 2021

Total comprehensive income for the period

Profit for the nine months period ended March 31, 2022

Share of other comprehensive loss from associated company - net of tax

Total comprehensive (loss) / income for the period

Transaction with owners, recognised directly in equity

Final cash dividend for the year ended June 30, 2021 @ Rs. 15 per share

Balance as at March 31, 2022

The annexed selected notes from 1 to 24 form an integral part of these unconsolidated condensed interim financial statements.

**UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022**

		March 31, 2022	March 31, 2021
	Note	-----Rupees-----	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations after working capital changes	17	6,166,022,427	795,407,995
Gratuity paid		(23,533,251)	(53,686,689)
Income tax paid - net		(518,108,099)	(50,165,293)
Long-term deposits - net		7,532,449	2,906,200
Net cash generated from operating activities		5,631,913,526	694,462,213
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditure (including CWIP)		(4,856,671,078)	(1,996,471,795)
Capital expenditure - intangibles		(1,000,000)	(10,306,200)
Investment in subsidiary company- unquoted shares		(633,262,500)	-
Short term investments		(643,094,448)	(125,418,766)
Proceeds from disposal of property, plant and equipment		512,203,201	562,616,552
Net cash used in investing activities		(5,621,824,825)	(1,569,580,209)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net receipts from long-term financing - secured		2,377,326,481	1,034,323,216
Lease repayments		(49,050,277)	(87,403,683)
Interest / mark-up paid		(849,413,913)	(603,133,903)
Dividends paid		(994,108,988)	(198,813,008)
Net cash generated from financing activities		484,753,303	144,972,622
Net increase / (decrease) in cash and cash equivalents		494,842,004	(730,145,374)
Cash and cash equivalents at the beginning of the period		(1,065,726,882)	(1,663,611,508)
Cash and cash equivalents at the end of the period	18	(570,884,878)	(2,393,756,882)

The annexed selected notes from 1 to 24 form an integral part of these unconsolidated condensed interim financial statements.

**NOTES TO THE UNCONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022****1 LEGAL STATUS AND OPERATIONS**

Ismail Industries Limited (the Company) was incorporated in Karachi, Pakistan as a private limited company on June 21, 1988. On November 01, 1989 the Company was converted into a public limited company. The registered office of the Company is situated at 17 - Bangalore Town, main Shahrah-e-Faisal, Karachi, Pakistan. The shares of the Company are quoted on Pakistan Stock Exchange. Principal activities of the Company are manufacturing and trading of sugar confectionery items, biscuits, potato chips, nutritional products, cast polypropylene (CPP) and biaxially-oriented polyethylene terephthalate (BOPET) film under the brands of 'CandyLand', 'Bisconni', 'Snackcity', 'Ismail nutrition' and 'Astro films' respectively.

2 SIGNIFICANT EVENTS AND TRANSACTIONS

During the period, the Company has made further investment in its associated company M/s. Ismail Resin (Private) Limited (IRPL) amounting to Rs. 633.26 million. All requisite regulatory requirements has been completed and IRPL has become the subsidiary of the Company by subscribing 112,500,000 shares as mentioned in note 8.2 to these consolidated condensed interim financial statements. The purpose of this investment is to setup polyester Resin (PET Resin) manufacturing plant, having the production capacity of 108,000 tons per annum.

3 STATEMENT OF COMPLIANCE

These unconsolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

4 BASIS OF PREPARATION

These unconsolidated condensed interim financial statements of the Company do not include all of the information and disclosure required in the unconsolidated annual audited financial statements and should be read in conjunction with the unconsolidated annual audited financial statements of the Company as at and for the year ended June 30, 2021. However, selected explanatory notes are included to explain the events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual financial statements.

The figures in the unconsolidated condensed interim statement of financial position, unconsolidated condensed interim statement of profit or loss and other comprehensive income, unconsolidated condensed interim statement of changes in equity and unconsolidated condensed interim statement of cash flows together with the relevant notes to the unconsolidated condensed interim financial statements for the nine-months period ended March 31, 2022 are not audited. Further, the figures for the three-months period ended March 31, 2022 and 2021 have not been reviewed by the auditors.

4.1 Functional and presentation currency

These unconsolidated condensed interim financial statements are presented in Pakistani Rupees which is also Company's functional currency and presentation currency.

4.2 Standards, amendments and interpretations to approved accounting standards**4.2.1 Standards, amendments and interpretations to the published standards that are relevant to the company and adopted in the current period**

The Company has adopted the following new standards, amendments to published standards and interpretations of IFRSs which became effective during the current period.

Standard or Interpretation**Effective Date
(Annual periods beginning
on or after)**

IFRS 9 - Fees in the '10 per cent' Test for Derecognition of Financial Liabilities (Amendments to IFRS 9)	January 1, 2022
Onerous Contracts - Cost of Fulfilling a Contract (Amendments to IAS 37)	January 1, 2022
IAS 16 - Proceeds before Intended Use (Amendments to IAS 16)	January 1, 2022
IAS 41 - Taxation in Fair Value Measurements (Amendment to IAS 41)	January 1, 2022
Updating a Reference to the Conceptual Framework (Amendments to IFRS 3)	January 1, 2022
Subsidiary as a First-time Adopter (Amendment to IFRS 1)	January 1, 2022

Adoption of the above standards have no significant effect on the amounts for the year ended March 31, 2022 except for those mentioned in change in accounting policy note.

4.2.2 Standards, amendments and interpretations to the published standards that are relevant but not yet effective and not early adopted by the Company

The following new standards, amendments to published standards and interpretations would be effective from the dates mentioned below against the respective standard or interpretation.

Standard or Interpretation**Effective Date
(Annual periods beginning
on or after)**

Classification of Liabilities as Current or Non-current (Amendments to IAS 1)	January 1, 2023
Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)	January 1, 2023
Definition of Accounting Estimates (Amendments to IAS 8)	January 1, 2023
Disclosure Initiative—Accounting Policies	January 1, 2023

The Company is in the process of assessing the impact of these standards, amendments and interpretations to the published standards on the unconsolidated condensed interim financial statements of the Company.

4.2.3 Standards, amendments and interpretations to the published standards that are not yet notified by the Securities and Exchange Commission of Pakistan (SECP)

Following new standards have been issued by the International Accounting Standards Board (IASB) which are yet to be notified by the SECP for the purpose of applicability in Pakistan.

Standard or Interpretation**IASB effective date
(Annual periods beginning
on or after)**

IFRS 17 'Insurance Contracts'	January 1, 2023
IFRS 1 'First-time Adoption of International Financial Reporting Standards'	July 1, 2009

5 SIGNIFICANT ACCOUNTING INFORMATION AND POLICIES

The accounting policies and methods of computation adopted for the preparation of these unconsolidated condensed interim financial statements are the same as those applied in the preparation of the unconsolidated financial statements for the year ended June 30, 2021.

6 USE OF JUDGEMENTS AND ESTIMATES AND FINANCIAL RISK MANAGEMENT

The estimates / judgements and associated assumptions used in the preparation of these unconsolidated condensed interim financial statements are consistent with those applied in the preparation of the unconsolidated financial statements of the Company for the year ended June 30, 2021.

The Company's financial risk management objective and policies are consistent with those disclosed in the Company's unconsolidated annual audited financial statements for the year ended June 30, 2021.

			(Un-audited) March 31, 2022	(Audited) June 30, 2021
			-----Rupees-----	
7 PROPERTY, PLANT AND EQUIPMENT	Note			
Operating fixed assets	7.2		20,332,155,786	19,820,929,398
Capital work in progress - at cost	7.3		3,608,515,081	976,371,736
			23,940,670,867	20,797,301,134
7.1 Right-of-use assets	7.2		40,959,881	82,762,838

7.2 Detail of additions and disposals to operating fixed assets and right-of-use assets during the nine-months period are as follows:

	(Un-audited)			
	Additions/Transfers		Disposals	
	-----At cost-----		-----At net book value-----	
	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
	----- Rupees -----			
Owned assets				
Building on leasehold land	398,282,094	783,956,044	6,138	-
Leasehold land	17,818,190	-	119,676,555	293,378,615
Plant and machinery	1,502,458,913	1,769,205,882	418,479	46,084
Furniture and fittings	12,110,724	18,516,330	531,849	-
Equipments	9,005,718	42,534,827	361,949	-
Computers	36,379,017	21,930,985	895,572	366,005
Vehicles	306,203,500	143,017,230	49,588,353	42,241,936
	2,282,258,156	2,779,161,298	171,478,895	336,032,640
Right-of-use assets				
Vehicles	(57,730,421)	817,992	-	-
	(57,730,421)	817,992	-	-
	2,224,527,735	2,779,979,290	171,478,895	336,032,640

7.3 Detail of additions in and transfers from capital work in progress during the nine-months period are as follows:

	(Un-audited)			
	Additions		Transfers	
	-----At cost-----			
	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
	----- Rupees -----			
Civil works	1,523,862,327	548,232,349	398,282,094	783,956,044
Plant and machinery	3,009,022,023	1,191,140,720	1,502,458,913	1,729,689,876
Electric installation	-	37,399,154	-	38,647,506
Equipment and Computer	-	-	-	7,168,300
	4,532,884,350	1,776,772,223	1,900,741,007	2,559,461,726
			(Un-audited)	(Audited)
			March 31, 2022	June 30, 2021
		Note	----- Rupees -----	

8 LONG-TERM INVESTMENTS

Investment in subsidiary companies- unquoted shares

Hudson Pharma (Private) Limited	8.1	1,605,984,000	1,605,984,000
Ismail Resin (Private) Limited	8.2	1,125,000,000	-
		2,730,984,000	1,605,984,000

Investment in associated undertakings

Ismail Resin (Private) Limited	8.2	-	491,737,500
The Bank of Khyber - quoted shares	8.3	3,149,139,553	3,180,003,578
		5,880,123,553	5,277,725,078

8.1 Hudson Pharma (Private) Limited

The Company holds 160,598,400 (June 2021: 160,598,400) shares of Hudson Pharma (Private) Limited (subsidiary), which is equivalent to 77.71% of total paid up capital of the subsidiary (June 2021: 77.71%). The subsidiary is incorporated as a private limited company. The registered office of the subsidiary is situated at 17 - Bangalore town, main Shahrah-e-Faisal, Karachi. Principal activities of the subsidiary are manufacturing, processing, compounding, formulating, importing, exporting, packaging, marketing, whole selling and retailing, trading and selling of all kinds of pharmaceutical drugs and medicines. The shares of subsidiary are not publicly listed on a stock exchange, hence published price quotes are not available. The financial reporting date of subsidiary is June 30.

The fair value of equity has been worked out at Rs.44.91/- per share, as determined by M/s. Munaf Yusuf & Co., Chartered Accountants, the valuation has been carried out using discounted cash flow method and thus there is no indication of any impairment in the value of these investment.

8.2 Ismail Resin (Private) Limited

As on reporting date, the Company holds 112,500,000 (June 2021: nil) shares of Ismail Resin (Private) Limited (subsidiary), which is equivalent to 75% of total paid up capital of the subsidiary. The subsidiary was incorporated in Karachi, Pakistan as a private limited company. The registered office of the subsidiary is situated at 17 - Bangalore Town, main Shahrah-e-Faisal, Karachi, Pakistan. Principal activities of the subsidiary are manufacturing and selling of Polyester Resin. The shares of subsidiary are not publicly listed on stock exchange, hence published price quotes are not available. The financial reporting date of subsidiary is June 30.

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
Share deposit money		
- opening balance	491,737,500	-
- increase during the period	633,262,500	491,737,500
	1,125,000,000	491,737,500
Converted into ordinary shares / advance	(1,125,000,000)	-
	-	491,737,500

8.3 The Bank of Khyber

The total shareholding of the Company in the Bank of Khyber (the Bank) is 256,555,982 (June 30, 2021: 256,555,982) shares which represents 24.43% of paid-up capital of the Bank (June 2021: 24.43%). In addition to this, the Company also has representation on the board of directors of the Bank. The Bank concludes its annual financial results on December 31 as required by the State Bank of Pakistan for financial institutions. Amounts in these unconsolidated condensed interim financial statements have been taken from audited financial statements of the Bank for the year ended December 31, 2021 and unaudited interim financial statement for the six months period ended June 30, 2021. Adjustment to confirm to the Bank's accounting policies is not warranted as the Bank is not engaged in like transaction under similar circumstances.

The market value of holding in the Bank as on March 31, 2022 was Rs. 3,848.34 million (June 30, 2021: Rs. 4,156.21 million).

This investment is accounted for under the equity method. The aggregate amount of the investment in associated company recognized in these unconsolidated condensed interim financial statements are as follows:

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
Carrying value at beginning of the period	3,180,003,578	3,441,616,096
Share of profit	121,026,531	379,554,402
Dividend received	-	(366,508,547)
Share of other comprehensive loss	(151,890,556)	(274,658,373)
	3,149,139,553	3,180,003,578

All transfers of funds to the Company, i.e. distribution of cash dividends, are subject to approval by means of a resolution passed by the shareholders of the associated company. During the period, no cash dividend has been received from the Bank of Khyber (June 30, 2021: Rs. 1.50 per share).

9 STORES AND SPARES

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
Stores and spare - gross	491,777,321	468,102,705
Provision for slow moving stores and spares	(8,591,420)	(8,591,420)
Stores and spares - net	483,185,901	459,511,285

		(Un-audited) March 31, 2022	(Audited) June 30, 2021
10 STOCK-IN-TRADE	Note	-----Rupees-----	
Raw materials	10.1	4,044,367,447	3,869,985,980
Packing materials	10.1	1,368,684,709	827,608,134
Work-in-process		359,597,012	232,913,398
Finished goods		2,178,963,064	2,639,927,750
		7,951,612,232	7,570,435,262

10.1 Raw materials and packing materials are stated at net of provision for slow moving items amounting to Rs. 41,284,033 (June 30, 2021: Rs. 13,576,856) and Rs. 129,293,365 (June 30, 2021: Rs. 152,848,549) respectively.

		(Un-audited) March 31, 2022	(Audited) June 30, 2021
11 TRADE DEBTS		-----Rupees-----	
Considered good		3,053,818,845	542,466,672
- export - secured		4,678,270,954	2,904,173,775
- local - unsecured		7,732,089,799	3,446,640,447
Allowance for expected credit loss		(100,970,640)	(100,970,640)
Trade debts - net		7,631,119,159	3,345,669,807

12 CASH AND BANK BALANCES			
Cash in hand		30,827,297	4,830,605
Cash with banks in:			
- current accounts- <i>conventional</i>		271,777,799	71,083,473
- current accounts- <i>islamic</i>		174,172,148	67,651,587
		476,777,244	143,565,665

13 LONG TERM FINANCES - secured

	(Un-audited)			(Audited)		
	March 31, 2022			June 30, 2021		
	-----Rupees-----					
	Conventional	Islamic	Total	Conventional	Islamic	Total
At beginning of the period / year	13,197,885,437	3,364,966,447	16,562,851,884	11,538,341,345	2,960,340,386	14,498,681,731
Obtained during the period / year	4,896,714,985	353,032,300	5,249,747,285	2,562,526,064	645,166,000	3,207,692,064
Repaid during the period / year	(2,058,164,991)	(814,255,812)	(2,872,420,803)	(902,981,972)	(240,539,939)	(1,143,521,911)
	16,036,435,431	2,903,742,935	18,940,178,366	13,197,885,437	3,364,966,447	16,562,851,884
Less: Current maturity	(2,671,451,789)	(725,980,213)	(3,397,432,002)	(2,575,582,046)	(1,096,516,272)	(3,672,098,318)
	13,364,983,642	2,177,762,722	15,542,746,364	10,622,303,391	2,268,450,175	12,890,753,566

13.1 These represent financings for property, plant and equipment. The above mentioned facilities are secured by way of creation of equitable mortgage and pari-passu / ranking charge over present and future fixed assets of the Company and personal guarantees of directors.

13.2 The Company's total limit for long term loan amounting to Rs. 27,335 million. (June 2021: Rs. 24,835 million)

		(Un-audited) March 31, 2022	(Audited) June 30, 2021
		-----Rupees-----	
14 TRADE AND OTHER PAYABLES	Note		
Trade creditors		5,888,202,578	1,869,718,370
Other liabilities		1,572,843,619	2,123,861,581
		7,461,046,197	3,993,579,951
15 SHORT TERM FINANCES - SECURED			
Term finances-conventional	15.1	1,564,776,553	-
Term finances-islamic	15.2	832,354,088	-
Export refinances	15.3	5,840,496,500	4,853,776,000
Finance against discounting of export bills / receivables	15.4	199,016,148	-
Running finance utilized under mark-up arrangement	15.5	1,047,662,122	1,209,292,547
		9,484,305,411	6,063,068,547

- 15.1** These represent facilities for term finances arranged from various banks aggregating to Rs. 1,565 million (June 2021: Rs. 1,005 million). These are secured against pari-passu / ranking hypothecation over stocks and book debts of the Company along with the personal guarantees of the directors. These carry mark-up at the rates ranging from 7.18% to 11.93% per annum (June 2021: 7.18% to 8.96% per annum).
- 15.2** These represent facilities for term finances arranged from various banks aggregating to Rs. 1,500 million (June 2021: Rs. 300 million). These are secured against pari-passu / ranking hypothecation over stocks and book debts of the Company along with the personal guarantees of the directors. These carry mark-up at the rates ranging from 8.70% to 12.59% per annum (June 2021: 6.81% to 8.63% per annum).
- 15.3** These represent facilities for export refinance arranged from various banks aggregating to Rs. 5,890 million (June 2021: Rs. 4,950.70 million). These are secured against pari-passu / ranking hypothecation of stocks, book debts and lien on export letters of credit of the Company along with the personal guarantees of the directors. These carried mark-up at the rate 0.25% to 1% above the State Bank of Pakistan (SBP) rate per annum (June 2021: 0.25% to 1% above SBP rate per annum).
- 15.4** These represent facilities for finance against discounting of export bills / receivable arranged from bank aggregating to Rs. 200 million (June 2021: Rs. nil). These are secured against pari-passu hypothecation over stocks and book debts of the Company along with the personal guarantees of the directors. These carry mark-up at the rate 1% above the State Bank of Pakistan (SBP) rate per annum (June 2021: nil).
- 15.5** These represent facilities for running finances available from various banks aggregated to Rs. 3,530 million (June 2021: Rs. 3,829.30 million). These are secured against pari-passu hypothecation of stocks, book debts and personal guarantees of the directors. These carry mark-up at the rates ranging from 7.61% to 11.54% per annum (June 2021: 7.35% to 8.28% per annum).

16 CONTINGENCIES AND COMMITMENTS

16.1 Contingencies

There are no material changes in the status of contingencies as reported in note no. 27 to the unconsolidated financial statements of the Company for the year ended June 30, 2021.

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
16.2 Commitments		
16.2.1 Outstanding letters of guarantee	2,299,766,080	2,112,978,557
16.2.2 Cross Corporate guarantees issued by the Company on behalf of subsidiaries / associated company	4,078,811,644	4,078,811,644
16.2.3 Outstanding letters of credit for:		
- capital expenditures	1,046,879,532	2,600,935,956
- others	2,312,564,744	1,018,228,669

16.2.4 The Company has executed sponsors support agreement with the lenders of M/s. Ismail Resin (Private) Limited for investment in the form of equity or subordinated debts to cover the cost over-run, or to cover the funding shortfall or any other obligation that may arise under financing documentations / agreements executed with them.

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
The Company's share of commitments of associated company	5,093,406	4,874,734
- Guarantees		
- Commitments	15,374,022	158,324,352

17 CASH GENERATED FROM OPERATIONS AFTER WORKING CAPITAL CHANGES

Note

	(Un-audited) March 31, 2022	(Un-audited) March 31, 2021
	-----Rupees-----	
Profit before taxation	2,394,054,715	1,700,266,283
Adjustments for non-cash and other items:		
Depreciation	1,583,625,407	1,210,465,642
Amortization charge	25,279,833	23,129,857
Gain on disposal of property, plant and equipment - net	(340,724,306)	(226,583,912)
Provision for staff gratuity scheme - unfunded	80,656,389	118,692,122
Provision for doubtful debts	-	5,000,000
Provision for slow moving - Stock in trade	4,151,993	-
Share of profit from associated undertaking	(121,026,531)	(230,991,373)
Unrealized exchange (gain) / loss	66,739,673	(9,038,171)
Finance cost	962,865,323	561,075,182
Net changes in working capital	1,510,399,931	(2,356,607,635)
Cash generated from operations after working capital changes	6,166,022,427	795,407,995

17.1 Working capital changes

Decrease / (Increase) in current assets

Stores and spares	(23,674,616)	(79,269,649)
Stock-in-trade	(385,328,963)	94,629,022
Trade debts	(3,485,449,352)	(1,056,861,031)
Loans and advances	(1,342,164,051)	(563,622,018)
Trade deposits and short-term prepayments	(25,079,524)	7,108,829
Other receivables	1,197,811	1,663,627
	(5,260,498,695)	(1,596,351,220)

(Decrease) / Increase in current liabilities

Trade and other payables	3,400,726,573	753,546,730
Short term finances - secured	3,582,867,289	(1,443,864,322)
Advances from customers - unsecured	(212,695,236)	(69,938,823)
	6,770,898,626	(760,256,415)
Net changes in working capital	1,510,399,931	(2,356,607,635)

18 CASH AND CASH EQUIVALENTS

Cash and bank balances	12	476,777,244	45,719,298
Running finances under mark-up arrangement	15	(1,047,662,122)	(2,439,476,180)
		(570,884,878)	(2,393,756,882)

		(Un-audited) March 31, 2022	(Audited) June 30, 2021
19.8 RECONCILIATION OF REPORTABLE SEGMENT ASSETS AND LIABILITIES	Note	-----Rupees-----	
Assets			
Total assets for reportable segments	19.2	43,831,382,274	34,968,998,317
Unallocated capital assets		1,218,328,190	743,257,467
Long term investments	8	5,880,123,553	5,277,725,078
Total assets		<u>50,929,834,017</u>	<u>40,989,980,862</u>
Liabilities			
Total liabilities for reportable segments	19.4	17,589,645,772	11,246,247,762
Deferred liabilities		2,338,846,774	1,843,977,690
Long term finance - secured	13	18,940,178,366	16,562,851,884
Lease liabilities		13,116,605	62,166,882
Total liabilities		<u>38,881,787,517</u>	<u>29,715,244,219</u>

20 EARNINGS PER SHARE - Basic and Diluted

	(Un-audited) March 31, 2022	(Un-audited) March 31, 2021
	-----Rupees-----	
Earnings per share		
Profit for the period	<u>1,897,770,928</u>	<u>1,501,269,348</u>
	----- (Number) -----	
Weighted average number of ordinary shares during the period	<u>66,356,940</u>	<u>66,356,940</u>
	----- (Rupees) -----	
Basic earnings per share	<u>28.60</u>	<u>22.62</u>

As at March 31, 2022 there is no diluted effect on the basic earning per share of the Company.

21 TRANSACTIONS AND BALANCES WITH RELATED PARTIES

Detail of transactions and balances with related parties during the period, other than those which have been specifically disclosed elsewhere in the unconsolidated condensed interim financial statements are as follows:

	(Un-audited) March 31, 2022	March 31, 2021
Transactions	-----Rupees-----	
Plastiflex Films (Private) Limited		
<i>Common Directorship</i>		
- Purchase of raw and packing materials	46,488,528	65,958,338
- Metallization service	(23,635,147)	(21,024,890)
- Recovery against sales	29,376,871	20,821,943
- Payment against purchases	(31,048,726)	(75,225,245)
Ismail Resin (Private) Limited		
Sale of land	446,500,000	-
Bank Guarantee issued	20,000,000	1,200,000,000
Hudson Pharma (Private) Limited		
Bank Guarantee issued	-	578,811,644
Others		
Remuneration to directors and other key management personnel:		
Chief Executive Officer	12,841,668	8,400,000
Directors	10,854,167	7,200,000
Executives	455,819,399	208,590,030
	<u>479,515,234</u>	<u>224,190,030</u>

In addition to the above, Company maintained cars are provided to the chief executive officer, directors and executives.

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
Balances		
Plastiflex Films (Private) Limited		
-Payable to associate - net	<u>23,141,613</u>	<u>1,960,087</u>

22 FAIR VALUE MEASUREMENT

The Company's financial risk management objectives and policies are consistent with that disclosed in the annual financial statements for the year ended June 30, 2021. There is no change in the nature and corresponding hierarchies of fair value levels of financial instruments from those as disclosed in the audited financial statements of the Company for the year ended June 30, 2021.

The carrying values of financial assets and liabilities are approximate of their fair values. The table below analyzes financial assets that are measured at fair value, by valuation method.

The different levels have been defined as follows:

- Level 1 : Quoted prices in active markets for identical assets and liabilities;
- Level 2 : Observable inputs; and
- Level 3 : Unobservable inputs

The Company held the following financial assets at fair value;

	March 31, 2022			Total	June 30, 2021
	(Level 1)	(Level 2)	(Level 3)		
	-----Rupees-----				
Investment in associated company	3,149,139,553	-	-	3,149,139,553	3,180,003,578
Short term investment	194,840,000	766,636,038	-	961,476,038	318,381,590
	3,343,979,553	766,636,038	-	4,110,615,591	3,498,385,168

23 FINANCIAL RISK MANAGEMENT

The Company's financial risk management objectives and policies are consistent with those disclosed in the unconsolidated financial statements for the year ended June 30, 2021.

24 DATE OF AUTHORIZATION FOR ISSUE

These unconsolidated condensed interim financial statements were authorized for issue on April 22, 2022 by the Board of the Company.

**CONSOLIDATED CONDENSED INTERIM
FINANCIAL INFORMATION (UN-AUDITED)
FOR THE NINE MONTHS PERIOD
ENDED MARCH 31, 2022**

**CONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT MARCH 31, 2022**

		(Un-audited) March 31, 2022	(Audited) June 30, 2021
	Note	-----Rupees-----	
ASSETS			
Non-current assets			
Property, plant and equipment	7	27,527,761,256	21,817,195,645
Right-of-use assets	7.1	40,959,881	82,762,838
Intangible assets		9,450,950	33,730,783
Goodwill		12,173,560	11,959,187
Long term investments	8	3,149,139,553	3,671,741,078
Long term deposits		24,663,599	31,458,748
Total non-current assets		30,764,148,799	25,648,848,279
Current assets			
Stores and spares	9	510,223,379	481,325,971
Stock-in-trade	10	8,104,670,309	7,723,683,283
Trade debts	11	7,756,510,678	3,393,522,541
Loans and advances		2,163,478,292	1,633,606,052
Trade deposits and short-term prepayments		77,034,256	39,453,161
Short term investment		1,408,714,491	318,381,590
Other receivables		198,671,066	117,644,543
Taxation - net		1,326,154,947	1,273,215,243
Cash and bank balances	12	500,136,899	158,547,846
Total current assets		22,045,594,317	15,139,380,230
Total assets		52,809,743,116	40,788,228,509
EQUITY AND LIABILITIES			
Share capital and reserves			
Authorized share capital			
250,000,000 (June 30, 2021: 250,000,000) ordinary shares of Rs. 10 each		2,500,000,000	2,500,000,000
Issued, subscribed and paid-up share capital		663,569,400	663,569,400
Non-controlling interest		461,676,998	116,036,838
Reserves		10,355,405,164	9,686,368,083
Total shareholders' equity		11,480,651,562	10,465,974,321
Non-current liabilities			
Long-term finances - secured	13	16,290,271,867	13,115,268,004
Lease liabilities		-	19,401,180
Sponsors' loan		1,163,126,504	-
Deferred liabilities		2,362,252,927	2,316,501,620
Total non-current liabilities		19,815,651,298	15,451,170,804
Current liabilities			
Trade and other payables	14	7,667,460,429	4,033,432,976
Accrued mark-up		286,629,855	166,153,705
Short-term finances - secured	15	9,634,305,411	6,168,068,547
Current portion of:			
- long-term finances - secured	13	3,543,750,720	3,878,636,296
- Lease liabilities		13,116,605	42,765,702
Unclaimed Dividend		4,147,708	2,902,597
Advances from customers - unsecured		364,029,528	579,123,561
Total current liabilities		21,513,440,256	14,871,083,384
Total liabilities		41,329,091,554	30,322,254,188
Total equity and liabilities		52,809,743,116	40,788,228,509

Contingencies and commitments

16

The annexed selected notes from 1 to 24 form an integral part of these consolidated condensed interim financial statements.

MUNSARIM SAIFULLAH
CHIEF EXECUTIVE OFFICER

MAQSOOD ISMAIL
DIRECTOR

ABDUL QADIR
CHIEF FINANCIAL OFFICER

**CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS
AND OTHER COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022**

Note	Nine-months Period Ended		Three-months Period Ended		
	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021	
	Rupees	Rupees	Rupees	Rupees	
Sales - gross	19.1	49,672,941,230	35,463,716,373	18,019,174,965	12,078,382,634
Sales returns and discounts		(1,956,940,916)	(1,531,737,626)	(787,957,444)	(527,497,363)
Export Rebate		22,879,618	13,691,682	1,903,288	2,895,813
		(1,934,061,298)	(1,518,045,944)	(786,054,156)	(524,601,550)
		47,738,879,932	33,945,670,429	17,233,120,809	11,553,781,084
Sales tax		(5,770,709,067)	(4,475,120,186)	(1,946,120,682)	(1,493,034,099)
Sales - net		41,968,170,865	29,470,550,243	15,287,000,127	10,060,746,985
Cost of sales	19.1	(34,382,236,386)	(23,567,731,462)	(12,535,308,700)	(7,872,387,654)
Gross profit		7,585,934,479	5,902,818,781	2,751,691,427	2,188,359,331
Selling and distribution expenses		(3,934,371,193)	(3,630,829,934)	(1,256,614,321)	(1,376,184,987)
Administrative expenses		(681,411,818)	(607,426,775)	(207,916,264)	(258,239,205)
Operating profit		2,970,151,468	1,664,562,072	1,287,160,842	553,935,139
Other operating expenses		(385,004,773)	(234,602,454)	(137,176,381)	(73,244,239)
		2,585,146,695	1,429,959,618	1,149,984,461	480,690,900
Other income		555,250,729	343,226,626	54,121,396	26,101,636
		3,140,397,424	1,773,186,244	1,204,105,857	506,792,536
Finance cost		(994,700,445)	(584,932,309)	(390,196,110)	(167,964,246)
		2,145,696,979	1,188,253,935	813,909,747	338,828,290
Share of profit from associated company - net		121,026,531	230,991,373	79,370,638	122,012,640
Profit before taxation		2,266,723,510	1,419,245,308	893,280,385	460,840,930
Taxation		(502,585,197)	(198,996,935)	(208,206,212)	65,434,303
Profit after taxation		1,764,138,313	1,220,248,373	685,074,173	526,275,233
Profit for the period attributable to:					
Shareholders of the Holding Company		1,793,498,153	1,282,874,208	686,146,593	541,585,322
Non-controlling interest		(29,359,840)	(62,625,835)	(1,072,420)	(15,310,089)
		1,764,138,313	1,220,248,373	685,074,173	526,275,233
Other Comprehensive (loss) / income					
Item that will not be reclassified to consolidated statement of profit or loss in subsequent periods					
Unrealized income / (loss) on remeasurement of investment classified as fair value through OCI - net of tax		-	(3,663,600)	-	-
Share of other comprehensive loss from associated undertaking - net of tax		(129,106,973)	(193,668,319)	(83,300,708)	(20,472,472)
Other comprehensive loss for the period - net of tax		(129,106,973)	(197,331,919)	(83,300,708)	(20,472,472)
Total comprehensive income for the period		1,635,031,340	1,022,916,454	601,773,465	505,802,761
Total comprehensive income for the period attributable to:					
Shareholders of the Holding Company		1,664,391,180	1,085,542,289	602,845,885	521,112,850
Non-controlling interest		(29,359,840)	(62,625,835)	(1,072,420)	(15,310,089)
		1,635,031,340	1,022,916,454	601,773,465	505,802,761
Earnings per share - basic & diluted	20	27.03	19.33	10.34	8.16

The annexed selected notes from 1 to 24 form an integral part of these consolidated condensed interim financial statements.

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022

Issued, subscribed and paid-up share capital	Capital reserve		Revenue reserve			Total reserves	Non-Controlling Interest	Total shareholders' equity
	Share premium	Amalgamation reserves	Share of OCI from associated company	Remeasurement of investments at fair value through OCI	Unappropriated profit			
663,569,400	1,472,531,500	916,862,067	41,535,172	-	6,158,470,644	8,589,399,383	195,749,872	9,448,718,655
-	-	-	-	-	1,282,874,208	1,282,874,208	(62,625,835)	1,220,248,373
-	-	-	-	(3,663,600)	-	(3,663,600)	-	(3,663,600)
-	-	-	(193,668,319)	-	-	(193,668,319)	-	(193,668,319)
-	-	-	(193,668,319)	-	1,282,874,208	1,089,542,289	(62,625,835)	1,022,914,544
663,569,400	1,472,531,500	916,862,067	(32,133,147)	(3,663,600)	(199,070,820)	(199,070,820)	-	(199,070,820)
-	-	-	-	-	7,282,274,052	9,475,870,852	133,124,137	10,272,564,289
663,569,400	1,472,531,500	916,862,067	(19,924,445)	(3,857,616)	7,492,756,577	9,866,368,083	116,036,838	10,465,974,321
-	-	-	-	-	1,793,498,153	1,793,498,153	(29,359,840)	1,764,138,313
-	-	-	-	-	-	-	375,000,000	375,000,000
-	-	-	(129,106,973)	-	-	(129,106,973)	-	(129,106,973)
-	-	-	(129,106,973)	-	1,793,498,153	1,664,391,180	345,640,160	2,010,031,340
663,569,400	1,472,531,500	916,862,067	(32,031,418)	(3,857,616)	(695,354,099)	(995,354,099)	-	(995,354,099)
-	-	-	-	-	8,290,900,633	10,355,403,64	461,676,998	11,480,651,562

Balance as at July 01, 2020 - audited
Total comprehensive income / (loss) for the period
Profit for the nine months period ended March 31, 2021
Unrealized loss on remeasurement of investment classified as fair value through OCI - net of tax
Share of other comprehensive loss from associated company - net of tax
Total comprehensive income / (loss) for the period
Transaction with owners, recognised directly in equity
Final cash dividend for the year ended June 30, 2020 @ Rs. 3 per share
Balance as at March 31, 2021
Total comprehensive income / (loss) for the period
Balance as at July 01, 2021 - audited
Total comprehensive income / (loss) for the period
Profit / (loss) for the nine months period ended March 31, 2022
NOCI recognized on acquisition
Share of other comprehensive loss from associated company - net of tax
Total comprehensive income / (loss) for the period
Final cash dividend for the year ended June 30, 2021 @ Rs. 15 per share
Balance as at March 31, 2022

The annexed selected notes from 1 to 24 form an integral part of these consolidated condensed interim financial statements.

MUNSARIM SAIFULLAH
CHIEF EXECUTIVE OFFICER

MAQSOOD ISMAIL
DIRECTOR

ABDUL QADIR
CHIEF FINANCIAL OFFICER

**CONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022**

		March 31, 2022	March 31, 2021
	Note	-----Rupees-----	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations after working capital changes	17	6,194,904,095	603,724,246
Gratuity paid		(28,949,393)	(58,266,776)
Income taxes paid - net		(533,938,238)	(45,895,905)
Long-term deposits - net		6,795,149	1,971,201
Net cash generated from operating activities		5,638,811,613	501,532,766
CASH FLOWS FROM INVESTING ACTIVITIES			
Capital expenditure (including CWIP)		(6,240,129,055)	(2,087,776,452)
Capital expenditure - intangibles		(1,000,000)	(10,306,200)
Acquisition of subsidiary net of cash acquired		(450,855,596)	-
Short term investments		(730,981,430)	(125,418,766)
Proceeds from disposal of property, plant and equipment		513,546,485	570,220,369
Net cash used in investing activities		(6,909,419,596)	(1,653,281,049)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net receipts from long-term financing - secured		2,529,260,287	1,080,275,081
Sponsors' loan		1,163,126,504	-
Lease repayments		(49,050,277)	(87,403,684)
Interest / mark-up paid		(875,400,065)	(628,124,288)
Dividends paid		(994,108,988)	(198,813,009)
Net cash generated from financing activities		1,773,827,461	165,934,100
Net increase / (decrease) in cash and cash equivalents		503,219,478	(985,814,183)
Cash and cash equivalents at the beginning of the period		(1,050,744,701)	(1,355,922,289)
Cash and cash equivalents at the end of the period	18	(547,525,223)	(2,341,736,472)

The annexed selected notes from 1 to 24 form an integral part of these consolidated condensed interim financial statements.

NOTES TO THE CONSOLIDATED CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED) FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2022

1 LEGAL STATUS AND OPERATIONS

The Group consist of:

Holding Company: Ismail Industries Limited

Subsidiary Companies: Hudson Pharma (Private) Limited and Ismail Resin (Private) Limited

a) Ismail Industries Limited

The Holding Company was incorporated in Karachi, Pakistan as a private limited company on June 21, 1988. On November 01, 1989 the Holding Company was converted into a public limited company. The registered office of the Holding Company is situated at 17 - Bangalore Town, Main Shahrah-e-Faisal, Karachi, Pakistan. The shares of the Holding Company are quoted on Pakistan Stock Exchange. The principal activities of the Holding Company are manufacturing and trading of sugar confectionery items, biscuits, potato chips, nutritional products, cast polypropylene (CPP) and biaxially-oriented polyethylene terephthalate (BOPET) film under the brands of 'CandyLand', 'Bisconni', 'Snackcity', 'Ismail nutrition' and 'Astro films' respectively.

b) Hudson Pharma (Private) Limited

The subsidiary company was incorporated in Pakistan as a private limited company on May 5, 2010, under the repealed Companies Ordinance, 1984 (now Companies Act, 2017). The registered office of the subsidiary company is located at 17 - Bangalore Town, Main Shahrah-e-Faisal, Karachi. Principal activities of the company are manufacturing, processing, compounding, formulating, importing, exporting, packaging, marketing, wholesale and retail, trading and selling of all kinds of pharmaceutical, animal health, allied consumer products, drugs and medicines.

c) Ismail Resin (Private) Limited

The subsidiary company was incorporated in Karachi, Pakistan on January 13, 2021, under the Companies Act, 2017 as a private limited company. The registered office/ head office of the subsidiary company is situated at 17 - Bangalore Town, Main Shahrah-e-Faisal, Karachi, Pakistan. Principal activities of the company are manufacturing and selling of Polyester Resin.

2 SIGNIFICANT EVENTS & TRANSACTIONS

During the period, the Holding Company has made further investment in its associated company M/s. Ismail Resin (Private) Limited (IRPL) amounting to Rs. 633.26 million. All requisite regulatory requirements has been completed and IRPL has become the subsidiary of the Holding Company by subscribing 112,500,000 shares. The purpose of this investment is to setup Polyester Resin (PET Resin) manufacturing plant, having the production capacity of 108,000 tons per annum.

3 STATEMENT OF COMPLIANCE

These consolidated condensed interim financial statements of the Group have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

4 BASIS OF PREPARATION

These consolidated condensed interim financial statements of the Group do not include all of the information and disclosure required in the consolidated annual audited financial statements and should be read in conjunction with the consolidated annual audited financial statements of the Group as at and for the year ended June 30, 2021. However, selected explanatory notes are included to explain the events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements.

The figures in the consolidated condensed interim statement of financial position, consolidated condensed interim statement of profit or loss and other comprehensive income, consolidated condensed interim statement of changes in equity and consolidated condensed interim statement of cash flows together with the relevant notes to the consolidated condensed interim financial statements for the nine-months period ended March 31, 2022 are not audited. Further, the figures for the three-months period ended March 31, 2022 and 2021 have not been reviewed by the auditors.

4.1 Functional and presentation currency

These consolidated condensed interim financial statements are presented in Pakistani Rupees which is also Group's functional currency and presentation currency.

4.2 Standards, amendments and interpretations to approved accounting standards

4.2.1 Standards, amendments and interpretations to the published standards that are relevant to the Group and adopted in the current period

The Group has adopted the following new standards, amendments to published standards and interpretations of IFRSs which became effective during the current period.

Standard or Interpretation	Effective Date (Annual periods beginning on or after)
IFRS 9 - Fees in the '10 per cent' Test for Derecognition of Financial Liabilities (Amendments to IFRS 9)	January 1, 2022
Onerous Contracts - Cost of Fulfilling a Contract (Amendments to IAS 37)	January 1, 2022
IAS 16 - Proceeds before Intended Use (Amendments to IAS 16)	January 1, 2022
IAS 41 - Taxation in Fair Value Measurements (Amendment to IAS 41)	January 1, 2022
Updating a Reference to the Conceptual Framework (Amendments to IFRS 3)	January 1, 2022
Subsidiary as a First-time Adopter (Amendment to IFRS 1)	January 1, 2022

Adoption of the above standards have no significant effect on the amounts for the period ended March 31, 2022.

4.2.2 Standards, amendments and interpretations to the published standards that are relevant but not yet effective and not early adopted by the Group

The following new standards, amendments to published standards and interpretations would be effective from the dates mentioned below against the respective standard or interpretation.

Standard or Interpretation	Effective Date (Annual periods beginning on or after)
Classification of Liabilities as Current or Non-current (Amendments to IAS 1)	January 1, 2023
Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)	January 1, 2023
Definition of Accounting Estimates (Amendments to IAS 8)	January 1, 2023
Disclosure Initiative—Accounting Policies	January 1, 2023

The Group is in the process of assessing the impact of these standards, amendments and interpretations to the published standards on the consolidated condensed interim financial statements of the Group.

4.2.3 Standards, amendments and interpretations to the published standards that are not yet notified by the Securities and Exchange Commission of Pakistan (SECP)

Following new standards have been issued by the International Accounting Standards Board (IASB) which are yet to be notified by the SECP for the purpose of applicability in Pakistan.

Standard or Interpretation	IASB effective date (Annual periods beginning on or after)
IFRS 17 'Insurance Contracts'	January 1, 2023
IFRS 1 'First-time Adoption of International Financial Reporting Standards'	July 1, 2009

5 SIGNIFICANT ACCOUNTING INFORMATION AND POLICIES

The accounting policies and methods of computation adopted for the preparation of these consolidated condensed interim financial statements are the same as those applied in the preparation of the consolidated financial statements for the year ended June 30, 2021.

6 USE OF JUDGEMENTS AND ESTIMATES AND FINANCIAL RISK MANAGEMENT

The estimates / judgements and associated assumptions used in the preparation of these consolidated condensed interim financial statements are consistent with those applied in the preparation of the consolidated financial statements of the Group for the year ended June 30, 2021.

The Group's financial risk management objectives and policies are consistent with those disclosed in the Group's consolidated annual audited financial statements for the year ended June 30, 2021.

7 PROPERTY, PLANT AND EQUIPMENT

	Note	(Un-audited) March 31, 2022	(Audited) June 30, 2021
-----Rupees-----			
Operating fixed assets	7.2	21,840,093,919	20,818,215,632
Capital work in progress - at cost	7.3	5,687,667,337	998,980,013
		27,527,761,256	21,817,195,645
7.1 Right-of-use assets	7.2	40,959,881	82,762,838

7.2 Detail of additions and disposals of operating and right-of-use assets during the nine-months period are as follows:

	(Un-audited)			
	Additions/Transfers		Disposals	
	-----At cost-----		-----At net book value-----	
	March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
	----- Rupees -----			
Owned assets				
Building on leasehold land	399,395,726	789,897,532	6,138	293,378,615
Leasehold land	450,718,190	-	119,676,555	-
Plant and machinery	1,502,562,619	1,784,885,190	418,479	46,084
Furniture and fittings	13,104,066	18,560,750	531,849	-
Equipment	156,620,242	44,253,297	361,949	-
Computers	38,847,830	22,640,257	895,572	366,005
Vehicles	310,971,322	151,384,730	50,742,621	42,241,936
	2,872,219,995	2,811,621,756	172,633,163	336,032,640
Right-of-use assets				
Vehicles	(57,730,421)	817,992	-	-
	(57,730,421)	817,992	-	-
	2,814,489,574	2,812,439,748	172,633,163	336,032,640

7.3 Detail of additions in and transfers from capital work-in-progress during the nine-months period are as follows:

		(Un-audited)	
		Additions	Transfers
		-----At cost-----	-----At net book value-----
		March 31, 2022	March 31, 2021
		-----Rupees-----	
Civil works		2,225,082,005	599,640,974
Leasehold land		942,130,856	-
Plant and machinery		3,743,416,700	1,034,677,866
Electric installation		-	37,399,154
Equipment and computers		111,698,768	4,554,943
Capitalization of trial production		-	159,343,484
		7,022,328,329	1,835,616,421

	Note	(Un-audited) March 31, 2022	(Audited) June 30, 2021
-----Rupees-----			
8 LONG-TERM INVESTMENTS			
<i>Investment in associated undertakings</i>			
Share deposit money		-	491,737,500
The Bank of Khyber - quoted shares	8.1	3,149,139,553	3,180,003,578
		3,149,139,553	3,671,741,078

8.1 The Bank of Khyber

The total shareholding of the Holding Company including the recently bonus entitlement of 5% announced by the Bank of Khyber (the Bank) is 256,555,982 (June 30, 2021: 256,555,982) shares which represents 24.43% of paid-up capital of the Bank (June 2021: 24.43%). In addition to this, the Holding Company also has representation on the board of directors of the Bank. The Bank concludes its annual financial results on December 31 as required by the State Bank of Pakistan for financial institutions. Amounts in these consolidated condensed interim financial statements have been taken from audited financial statements of the Bank for the period ended December 31, 2021 and unaudited interim financial statement for the six-months period ended June 30, 2021. Adjustment to confirm to the Bank's accounting policies is not warranted as the Bank is not engaged in like transaction under similar circumstances.

The market value of holding in the Bank as on March 31, 2022 was Rs. 3,848.34 million (June 30, 2021: Rs. 4,156.21 million).

This investment is accounted for under the equity method. The aggregate amount of the investment in associated company recognized in these consolidated condensed interim financial statements are as follows:

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
Carrying value at beginning of the period	3,180,003,578	3,441,616,096
Share of profit	121,026,531	379,554,402
Dividend received	-	(366,508,547)
Share of other comprehensive income / (loss)	(151,890,556)	(274,658,373)
	3,149,139,553	3,180,003,578

All transfers of funds to the Holding Company, i.e. distribution of cash dividends, are subject to approval by means of a resolution passed by the shareholders of the associated companies. During the period, no cash dividend has been received from the Bank of Khyber (June 30, 2021: Rs. 1.50 per share).

	Note	(Un-audited) March 31, 2022	(Audited) June 30, 2021
		-----Rupees-----	
9 STORES AND SPARES			
Stores and spares - gross		518,814,799	489,917,391
Provision for slow moving stores and spares		(8,591,420)	(8,591,420)
Stores and spares - net		510,223,379	481,325,971
10 STOCK-IN-TRADE			
Raw materials	10.1	4,104,814,461	3,929,756,610
Packing materials	10.1	1,388,447,209	842,685,060
Work-in-process		361,884,827	232,913,397
Finished goods		2,249,523,812	2,718,328,216
		8,104,670,309	7,723,683,283
10.1	Raw materials and packing materials are stated at net of provision for slow moving items amounting to Rs. 41,284,033 (June 30, 2021: Rs. 13,576,856) and Rs. 129,293,365 (June 30, 2021: Rs. 152,848,549) respectively.		
		(Un-audited) March 31, 2022	(Audited) June 30, 2021
		-----Rupees-----	
11 TRADE DEBTS			
Considered good		3,095,589,237	542,466,672
- export - secured		4,761,892,081	2,952,026,509
- local - unsecured		7,857,481,318	3,494,493,181
Allowance for expected credit loss		(100,970,640)	(100,970,640)
Trade debts - net		7,756,510,678	3,393,522,541

12 CASH AND BANK BALANCES

Cash in hand

Cash with banks in:

- current accounts- *conventional*- current accounts- *islamic*

(Un-audited) March 31, 2022	(Audited) June 30, 2021
-----Rupees-----	
41,585,978	5,518,264
283,660,579	84,939,262
174,890,342	68,090,320
500,136,899	158,547,846

13 LONG TERM FINANCES - secured

	(Un-audited)			(Audited)		
	March 31, 2022			June 30, 2021		
	-----Rupees-----					
	Conventional	Islamic	Total	Conventional	Islamic	Total
At beginning of the period / year	13,468,937,853	3,524,966,447	16,993,904,300	11,787,468,392	3,130,340,386	14,917,808,778
Obtained during the period / year	5,514,453,986	353,032,300	5,867,486,286	2,632,138,529	645,166,000	3,277,304,529
Repaid during the period / year	(2,183,112,187)	(844,255,812)	(3,027,367,999)	(950,669,068)	(250,539,939)	(1,201,209,007)
	16,800,279,652	3,033,742,935	19,834,022,587	13,468,937,853	3,524,966,447	16,993,904,300
	(2,777,770,507)	(765,980,213)	(3,543,750,720)	(2,742,120,024)	(1,136,516,272)	(3,878,636,296)
Less: Current maturity	14,022,509,145	2,267,762,722	16,290,271,867	10,726,817,829	2,388,450,175	13,115,268,004

13.1 These represent financings for property, plant, and equipment. The above mentioned facilities are secured by way of creation of equitable mortgage and first pari-passu / ranking charge over present and future fixed assets of the Group and personal guarantees of sponsors.

13.2 The Group's total limit for long term loan amounting to Rs. 31,762 million. (June 2021 Rs.25,762 million)

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
Trade creditors	6,019,804,481	1,886,612,724
Other liabilities	1,647,655,948	2,146,820,252
	7,667,460,429	4,033,432,976

15 SHORT TERM FINANCES - SECURED

Term finances - conventional	15.1	1,564,776,553	-
Term finances - islamic	15.2	982,354,088	105,000,000
Export refinances	15.3	5,840,496,500	4,853,776,000
Finance against discounting of export bills / receivables	15.4	199,016,148	-
Running finance utilized under mark-up arrangement	15.5	1,047,662,122	1,209,292,547
		9,634,305,411	6,168,068,547

15.1 These represent facilities for term finances arranged from various banks aggregating to Rs. 1,565 million (June 2021: Rs. 1,005 million). These are secured against pari-passu / ranking hypothecation over stocks and book debts of the Group along with the personal guarantees of the directors. These carry mark-up at the rates ranging from 7.18% to 11.93% per annum (June 2021: 7.18% to 8.96% per annum).

15.2 These represent facilities for term finances arranged from various banks aggregating to Rs. 1,650 million (June 2021: Rs. 450 million). These are secured against pari-passu / ranking hypothecation over stocks and book debts of the Group along with the personal guarantees of the directors. These carry mark-up at the rates ranging from 8.70% to 12.59% per annum (June 2021: 6.81% to 8.63% per annum).

15.3 These represented facilities for export refinance arranged from various banks aggregating to Rs. 5,890 million (June 2021: Rs. 4,950.70 million). These are secured against pari-passu / ranking hypothecation of stocks, book debts and lien on export letters of credits of the Group along with the personal guarantees of the directors. These carried mark-up at the rate 0.25% to 1% above the State Bank of Pakistan (SBP) rate per annum (June 2021: 0.25% to 1% above SBP rate per annum).

15.4 These represent facilities for finance against discounting of export bills / receivable arranged from bank aggregating to Rs. 200 million (June 2021: Rs. nil). These are secured against pari-passu hypothecation over stocks and book debts of the Group along with the personal guarantees of the directors. These carry mark-up at the rate 1% above the State Bank of Pakistan (SBP) rate per annum (June 2021: nil).

15.5 These represent facilities for running finances available from various banks aggregated to Rs. 3,530 million (June 2021: Rs. 3,829.30 million). These are secured against pari-passu hypothecation of stocks and book debts and personal guarantees of the directors. These carry mark-up at the rates ranging from 7.61% to 11.54% per annum (June 2021: 7.35% to 8.28% per annum).

16 CONTINGENCIES AND COMMITMENTS**16.1 Contingencies**

There are no material changes in the status of contingencies as reported in note no. 29 to the unconsolidated financial statements of the Group for the year ended June 30, 2021.

16.2 Commitments**16.2.1 Outstanding letter of guarantees****16.2.2 Cross Corporate guarantees issued by the Holding Company on behalf of subsidiaries / associated company****16.2.3 Outstanding letters of credit for:**

- capital expenditures

- others

The Holding Company's share of commitments of associated company

- Guarantees

- Commitments

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
	-----Rupees-----	
	2,321,882,945	2,113,128,557
	4,078,811,644	4,078,811,644
	4,788,470,913	2,850,901,463
	2,312,564,744	1,018,228,669
	5,093,406	4,874,734
	15,374,022	158,324,352

17 CASH GENERATED FROM OPERATIONS AFTER WORKING CAPITAL CHANGES

Profit before taxation

Note

Adjustments for non-cash and other items:

Depreciation

A amortization charge

Gain on disposal of property, plant and equipment - net

Provision for staff gratuity scheme - unfunded

Provision for doubtful debts

Provision for slow moving - Stock in trade

Share of profit from associated undertaking

Unrealized exchange Loss

Finance cost

Net decrease / (increase) in working capital

Cash generated from operations after working capital changes

	(Un-audited) March 31, 2022	(Un-audited) March 31, 2021
	-----Rupees-----	
	2,266,723,510	1,419,245,308
	1,661,781,079	1,295,892,252
	25,279,833	23,129,857
	(340,913,322)	(229,560,292)
	84,261,139	124,734,227
	-	5,000,000
	4,151,993	-
	(121,026,531)	(230,991,373)
	66,739,673	(9,038,171)
	994,700,445	584,932,309
	1,553,206,276	(2,379,619,871)
	6,194,904,095	603,724,246

17.1 Working capital changes**Decrease / (Increase) in current assets**

Stores and spares

Stock-in-trade

Trade debts

Loan and advances

Trade deposits and short-term prepayments

Other receivables

(Decrease) / Increase in current liabilities

Trade and other payables

Short term finances - secured

Advances from customers - unsecured

Net decrease / (increase) in working capital

	(28,897,408)	(77,892,069)
	(385,139,019)	102,702,326
	(3,562,988,137)	(1,094,078,590)
	(1,329,130,600)	(586,671,952)
	(37,581,095)	4,831,865
	(79,311,795)	109,905
	(5,423,048,054)	(1,650,998,515)
	3,563,481,074	785,181,787
	3,627,867,289	(1,443,864,322)
	(215,094,033)	(69,938,821)
	6,976,254,330	(728,621,356)
	1,553,206,276	(2,379,619,871)

18 CASH AND CASH EQUIVALENTS

Cash and bank balances

Running finances under mark-up arrangement

	500,136,899	97,739,708
	(1,047,662,122)	(2,439,476,180)
	(547,525,223)	(2,341,736,472)



19 SEGMENT INFORMATION

A segment is a distinguishable component of the Group that is engaged in business activities from which the Group earns revenues and incurs expenses and its results are regularly reviewed by the Group's chief operating decision maker to make decisions about resources to be allocated to the segment and losses to performance. Further, discrete financial information is available for each segment.

Based on internal management reporting structure and products produced and sold, the company is organized into the following four operating segments:

- Food Segment
- Feed Segment
- Pharma Segment
- Chemical Segment

Management segment the operating results of above mentioned segments separately for the purpose of making decisions about resources to be allocated and of assessing performance.

Segment revenue, segment result, cost, asset and liabilities for the period are as follows:

	(Un-audited)											
	Three months period ended						Nine months period ended					
	March 31, 2021		March 31, 2020		Total		March 31, 2021		March 31, 2020		Total	
Selling and distribution expenses	Total		Total		Total		Total		Total		Total	
	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020
Sales	80,412,237.50	17,678,424.12	343,028,245.24	2,814,323.33	11,059,638.00	97,976,311.33	25,445,752.66	9,543,226.67	648,970,311.33	18,378,319.33	343,028,245.24	2,814,323.33
Cost of sales	3,374,309.68	1,705,060.14	16,895,928.28	5,310,209.93	86,574,669.66	43,102,099.93	91,884,879.59	9,749,146.80	431,020,999.33	18,378,319.33	343,028,245.24	2,814,323.33
Export rebates	13,814,177.97	9,854,430.91	3,884,194.40	2,481,770.97	18,619,372.41	30,014,932.32	20,175,302.21	11,584,244.97	72,143,627.67	393,302.29	49,699,238.03	34,177,080.03
Loss	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)
Sales tax	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)
Net sales	(9,800,402.68)	(2,627,140.77)	(2,630,899.48)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)	(1,069,412,127.77)
Cost of sales	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Administrative expenses	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Net income	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Segment result	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Unaudited income and expenses	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Other operating income	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Other operating expenses	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Share of profit from associated undertakings	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Profit before taxation	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Income tax expense	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Profit for the period	(1,020,256.67)	(1,172,834.62)	(13,141,694.01)	(38,529,145.35)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)	(1,046,786.62)	(1,046,786.62)	(40,575,931.97)
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												
Food Segment												
Feed Segment												
Chemical Segment												
Pharmaceutical Segment												

		(Un-audited) March 31, 2022	(Audited) June 30, 2021
		-----Rupees-----	-----Rupees-----
19.9 RECONCILIATION OF REPORTABLE SEGMENT ASSETS AND LIABILITIES	Note		
Assets			
Total assets for reportable segments	19.2	48,442,275,373	36,373,229,964
Unallocated capital assets		1,218,328,190	743,257,467
Long term investment	8	3,149,139,553	3,671,741,078
Total assets		52,809,743,116	40,788,228,509
Liabilities			
Total liabilities for reportable segments	19.4	19,143,105,588	11,422,205,316
Deferred liabilities		2,338,846,774	1,843,977,690
Long term finance - secured	13	19,834,022,587	16,993,904,300
Lease liabilities		13,116,605	62,166,882
Total liabilities		41,329,091,554	30,322,254,188

20 EARNINGS PER SHARE - Basic and Diluted

	(Un-audited) March 31, 2022	(Un-audited) March 31, 2021
	-----Rupees-----	-----Rupees-----
Basic earnings per share		
Profit for the period	1,793,498,153	1,282,874,208
	-----Number-----	-----Number-----
Weighted average number of ordinary shares as at March 31.	66,356,940	66,356,940
	-----Rupees-----	-----Rupees-----
Basic and diluted earnings per share	27.03	19.33

As at March 31, 2022 there is no diluted effect on the basic earnings per share of the Group.

21 TRANSACTIONS AND BALANCES WITH RELATED PARTIES

Detail of transactions and balances with related parties during the period, other than those which have been specifically disclosed elsewhere in the consolidated condensed interim financial statements are as follows:

	(Un-audited) March 31, 2022	March 31, 2021
	-----Rupees-----	-----Rupees-----
Transactions		
Plastiflex Films (Private) Limited		
<i>Common Directorship</i>		
- Purchase of raw and packing materials	46,488,528	65,958,338
- Metallization service	(23,635,147)	(21,024,890)
- Recovery against sales	29,376,871	20,821,943
- Payment against purchases	(31,048,726)	(75,225,245)
Others		
Remuneration to directors and other key management personnel:		
Chief Executive Officer	34,441,668	14,700,000
Directors	21,654,167	7,200,000
Executives	491,971,378	252,815,409
	548,067,213	274,715,409

In addition to the above, Group maintained cars are provided to the chief executive officer, directors and executives.

	(Un-audited) March 31, 2022	(Audited) June 30, 2021
Balances	-----Rupees-----	
Plastiflex Films (Private) Limited		
-Payable to associate - net	23,141,613	1,960,087

22 FAIR VALUE MEASUREMENT

The Group's financial risk management objectives and policies are consistent with that disclosed in the annual financial statements for the year ended June 30, 2021. There is no change in the nature and corresponding hierarchies of fair value levels of financial instruments from those as disclosed in the audited financial statements of the Group for the year ended June 30, 2021.

The carrying values of financial assets and liabilities are approximate at their fair values. The table below analyzes financial assets that are measured at fair value, by valuation method.

The different levels have been defined as follows:

- Level 1 : Quoted prices in active markets for identical assets and liabilities;
- Level 2 : Observable inputs; and
- Level 3 : Unobservable inputs

The Group held the following financial assets at fair value;

	March 31, 2022			Total	June 30, 2021
	(Level 1)	(Level 2)	(Level 3)		
	-----Rupees-----				
Investment in associated undertaking	3,149,139,553	3,149,139,553	-	6,298,279,105	3,180,003,578
Short term Investment	194,840,000	1,213,874,491	-	1,408,714,491	318,381,590
	3,343,979,553	4,363,014,044	-	7,706,993,596	3,498,385,168

23 FINANCIAL RISK MANAGEMENT

The Group's financial risk management objectives and policies are consistent with those disclosed in the consolidated financial statements for the year ended June 30, 2021.

24 DATE OF AUTHORIZATION FOR ISSUE

These consolidated condensed interim financial statements were authorized for issue on April 22, 2022 by the Board of the Group.



ISMAIL INDUSTRIES LIMITED

HEAD OFFICE

17-BANGALORE TOWN, SHAHRAH-E-FAISAL, KARACHI-75350, PAKISTAN.
TEL: (92-21) 3431 1172-76, FAX: (92-21) 3454 7843, 3454 1094

FACTORIES

UNIT 1: C-230, H.I.T.E. HUB, BALOCHISTAN, PAKISTAN.
TEL: (92-853) 302526-302392

UNIT 2: B-140, H.I.T.E. HUB, BALOCHISTAN, PAKISTAN.
TEL: (92-853) 302589, FAX: (92-853) 302408

UNIT 3: G-1, H.I.T.E. HUB, BALOCHISTAN, PAKISTAN.
TEL: (92-853) 302611, FAX: (92-853) 302611, 303817

UNIT 4: G-22, 23, H.I.T.E. HUB, BALOCHISTAN, PAKISTAN.
TEL: (92-853) 303193, 303177, FAX: (92-853) 302527

UNIT 5: 38-C, 39, 39-A, 42-C, SUNDAR INDUSTRIAL ESTATE,
RAIWIND ROAD, LAHORE, PAKISTAN. TEL: (92-42) 36140972

UNIT 6: D-91, D-92 & D-94, NORTH WESTERN INDUSTRIAL ZONE,
PORT QASIM AUTHORITY, KARACHI. TEL: (92-21) 34154169-70, FAX: (92-21) 34154176

UNIT 7: E-164 TO E-168, NORTH WESTERN INDUSTRIAL ZONE,
PORT QASIM AUTHORITY, KARACHI. TEL: (92-21) 34154171-73, FAX: (92-21) 34154176

UNIT 8: E-154 TO E-157, NORTH WESTERN INDUSTRIAL ZONE,
PORT QASIM AUTHORITY, KARACHI. TEL: (92-21) 34154174-75, FAX: (92-21) 34154176

UNIT 9: G-1A, H.I.T.E., HUB, BALOCHISTAN, PAKISTAN.
TEL: (92-853) 363495, 303510